First drug test for metastatic uveal melanoma with specific gene changes
Treatments studied
Part of Cancer, Digestive system, Eyes & vision, Skin clinical trials.
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to sign consent paperwork
- Have metastatic uveal melanoma confirmed by tumor testing (and it must be measurable on scans)
- Be well enough to take study treatment (performance status 0–1) and expect to live more than 3 months
- Have adequate blood and organ function based on screening labs
- Have a tumor that is matched to the study (GNAQ/11 mutations or PRKC fusions), with required lab-confirmed testing
- Agree to use effective birth control if you could become pregnant or father a child
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
This Phase 2 trial tests binimetinib plus imatinib in people with advanced melanoma that cannot be removed with surgery and that has a KIT mutation. It’s for melanoma that has gotten worse after standard treatment (or where standard treatment isn’t possible or tolerated).
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.